Source: CureToday articles
HT-KIT, a novel targeted therapy for GIST, demonstrated the ability to reduce tumor burden in humanized mouse models and induce tumor cell death.
Recent Content
- Expert: Pharmacists’ Role in Education, Adoption, and Market Sustainability for Biosimilars
- AACR 2025: Off-the-Shelf Machine Learning Models May Bridge Diagnostic Gaps in Global Skin Cancer Care
- AACR 2025: Off-the-Shelf CAR NK Therapy SENTI-202 Shows Potential for Complete Remission in R/R AML
- Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models
- Healer, Mentor and Leader
- AACR 2025: Oral Investigational Agent Zoldonrasib Elicits Objective Responses in Patients With KRAS G12D-Mutated NSCLC
- FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors
- Hydroxyurea Produces Long-Term Clinical Benefits in Pediatrics With Sickle Cell Anemia
- Crafting an Individual Treatment Plan for Patients With Prostate Cancer
- DPYD Testing Gains Ground: NCCN Guideline Update Reflects Decades of Work Toward Safer Chemotherapy